Skip to main
AXSM
AXSM logo

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 47%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. reported third-quarter revenues of $136.1 million, significantly exceeding consensus estimates and demonstrating a robust year-over-year growth of 69% and a quarter-over-quarter increase of 14%. The company has improved payer coverage to 85%, which enhances the commercial potential of its therapies, particularly with the positive outcomes from ongoing Phase III studies, including the FOCUS study for adult ADHD. Furthermore, projections indicate that revenue will outpace operating costs, potentially leading to improved operating margins and a forecasted cash flow positivity by 2026.

Bears say

Axsome Therapeutics Inc. faces a negative outlook primarily due to a revised revenue forecast for 2025, reflecting a modest decline from previous estimates, indicating potential market challenges. Several significant risks threaten the company's performance, including lower-than-expected market access for its lead product AUVELITY, setbacks in key clinical trials, and challenges in securing timely approvals for pipeline candidates such as AXS-12 and AXS-14. Additionally, the company may encounter long-term dilution risks and competitive pressures that could hinder its commercial success within the CNS disorder treatment landscape.

Axsome Therapeutics (AXSM) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 47% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 17 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.